TrialNature communications2022

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.

Chih-Jung Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.